RecruitingEarly Phase 1NCT05917587

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes


Sponsor

Anna Stanhewicz, PhD

Enrollment

30 participants

Start Date

Sep 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metformin Hydrochloride and placebo for people with gestational diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin Hydrochloride

12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.

OTHERplacebo

12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.


Locations(1)

University of Iowa

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05917587


Related Trials